Evaluation of venous thromboembolism prophylaxis in patients with chronic liver disease
| Autor: | Christophe Sands, April C. Hurdle, Jennifer D. Twilla, Carmen B. Smith, Leonette O. Kemp |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Leadership and Management Length of hospitalization Hemorrhage Assessment and Diagnosis Vte prophylaxis Chronic liver disease End Stage Liver Disease Internal medicine medicine Humans In patient Thrombolytic Therapy cardiovascular diseases Intensive care medicine Care Planning Aged Retrospective Studies Retrospective review business.industry Health Policy Incidence (epidemiology) Anticoagulants General Medicine Venous Thromboembolism Middle Aged medicine.disease Hospital medicine Treatment Outcome Fundamentals and skills Female business Venous thromboembolism |
| Zdroj: | Journal of hospital medicine. 8(10) |
| ISSN: | 1553-5606 |
| Popis: | BACKGROUND The incidence of venous thromboembolism (VTE) in chronic liver disease (CLD) patients has been reported to be 0.5% to 6.3%. Studies report the use of thromboprophylaxis in CLD patients as suboptimal, with at least 75% of patients receiving no prophylaxis. OBJECTIVE To describe the use of VTE prophylaxis in CLD patients. DESIGN A retrospective review. SETTING Tertiary-care academic medical center. PATIENTS Inpatient admissions from August 2009 through July 2011 with CLD diagnosis. INTERVENTION None. MEASUREMENTS Initiation and type of thromboprophylaxis, incidence of VTE, bleeding events, hospital length of stay, in-hospital mortality, 30-day readmission for VTE. RESULTS Of the 410 patients included, 225 (55%) patients received thromboprophylaxis. For patients with international normalized ratio (INR) >2.0, a significant decrease in overall thromboprophylaxis use and pharmacologic prophylaxis use was seen compared to those with INR 1.4 to 2.0 (P = 0.013 and P 2.0 (P = 0.001). CONCLUSION The use of thromboprophylaxis in CLD patients is higher in our study than previous reports but remains suboptimal. Use of VTE pharmacologic prophylaxis does not appear to increase bleeding in CLD patients with INR ≤2.0. Further studies are needed to provide additional safety data. Journal of Hospital Medicine 2013;8:569–573. © 2013 Society of Hospital Medicine |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text